HeartCore signs 13th Go IPO consulting deal with PharmaBio; $800k fees plus warrant

HeartCore Enterprises, Inc.

Signed 13th Go IPO consulting agreement with PharmaBio Corporation, second contract in 2024.
Expected compensation: $500,000 in initial fees, $300,000 in success fees, and a warrant for 3% of PharmaBio common stock.
CEO cites recent $9M from warrant sale of a previous Go IPO client; expects 2024 to be strongest year.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.